Notably, patients with HR+/HER2- and HER2+ breast cancer subtypes were more likely to remain on their systemic therapy following MDRT, although whether this is due to inherit differences in prognosis or the effect of MDRT remains uncertain due to the lack of a control group. This evidence concerns the gene HR and breast carcinoma.